12/22
11:42 am
rapp
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? [Yahoo! Finance]
Low
Report
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? [Yahoo! Finance]
12/19
08:44 am
rapp
Rapport Therapeutics (NASDAQ:RAPP) was given a new $51.00 price target on by analysts at Wells Fargo & Company.
Medium
Report
Rapport Therapeutics (NASDAQ:RAPP) was given a new $51.00 price target on by analysts at Wells Fargo & Company.
12/19
07:19 am
rapp
Rapport Therapeutics (NASDAQ:RAPP) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Medium
Report
Rapport Therapeutics (NASDAQ:RAPP) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
12/18
07:00 am
rapp
Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/14
01:27 am
rapp
Rapport Therapeutics (NASDAQ:RAPP) was upgraded by analysts at
Wall Stre
Medium
Report
Rapport Therapeutics (NASDAQ:RAPP) was upgraded by analysts at
Wall Stre
12/9
07:21 am
rapp
Rapport Therapeutics (NASDAQ:RAPP) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Rapport Therapeutics (NASDAQ:RAPP) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/8
08:07 am
rapp
Rapport Therapeutics (NASDAQ:RAPP) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $47.00 price target on the stock.
Low
Report
Rapport Therapeutics (NASDAQ:RAPP) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $47.00 price target on the stock.
12/7
02:21 am
rapp
Rapport Therapeutics (RAPP) Valuation Check After a 60% Year-to-Date Share Price Surge [Yahoo! Finance]
Low
Report
Rapport Therapeutics (RAPP) Valuation Check After a 60% Year-to-Date Share Price Surge [Yahoo! Finance]
12/6
04:23 pm
rapp
RAP-219 Phase 2a Seizure Data and Planned Pivotal Trials Might Change The Case For Investing In Rapport Therapeutics (RAPP) [Yahoo! Finance]
Low
Report
RAP-219 Phase 2a Seizure Data and Planned Pivotal Trials Might Change The Case For Investing In Rapport Therapeutics (RAPP) [Yahoo! Finance]
12/6
01:36 am
rapp
Rapport Therapeutics (NASDAQ:RAPP) was downgraded by analysts at
Wall St
Low
Report
Rapport Therapeutics (NASDAQ:RAPP) was downgraded by analysts at
Wall St
12/6
01:36 am
rapp
Rapport Therapeutics (NASDAQ:RAPP) was downgraded by analysts at
Wall St
Low
Report
Rapport Therapeutics (NASDAQ:RAPP) was downgraded by analysts at
Wall St
12/5
09:00 am
rapp
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures
Medium
Report
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures
11/28
12:07 pm
rapp
Wall Street Analysts See a 74.99% Upside in Rapport Therapeutics, Inc. (RAPP): Can the Stock Really Move This High? [Yahoo! Finance]
Low
Report
Wall Street Analysts See a 74.99% Upside in Rapport Therapeutics, Inc. (RAPP): Can the Stock Really Move This High? [Yahoo! Finance]
11/25
07:00 am
rapp
Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting
Low
Report
Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting
11/20
06:02 am
rapp
Rapport Therapeutics (NASDAQ:RAPP) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
Low
Report
Rapport Therapeutics (NASDAQ:RAPP) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
11/19
08:07 am
rapp
Rapport Therapeutics (NASDAQ:RAPP) is now covered by analysts at BTIG Research. They set a "buy" rating and a $47.00 price target on the stock.
Medium
Report
Rapport Therapeutics (NASDAQ:RAPP) is now covered by analysts at BTIG Research. They set a "buy" rating and a $47.00 price target on the stock.
11/7
09:41 am
rapp
Rapport Therapeutics (NASDAQ:RAPP) had its price target raised by analysts at Citizens Jmp from $77.00 to $80.00. They now have a "market outperform" rating on the stock.
Low
Report
Rapport Therapeutics (NASDAQ:RAPP) had its price target raised by analysts at Citizens Jmp from $77.00 to $80.00. They now have a "market outperform" rating on the stock.
11/7
05:30 am
rapp
Rapport Therapeutics, Inc.'s (NASDAQ:RAPP) latest 5.7% decline adds to one-year losses, institutional investors may consider drastic measures [Yahoo! Finance]
Low
Report
Rapport Therapeutics, Inc.'s (NASDAQ:RAPP) latest 5.7% decline adds to one-year losses, institutional investors may consider drastic measures [Yahoo! Finance]
11/6
07:00 am
rapp
Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update
Low
Report
Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update
11/5
04:05 pm
rapp
Rapport Therapeutics to Participate in Upcoming Investor Conferences
Medium
Report
Rapport Therapeutics to Participate in Upcoming Investor Conferences
10/2
12:19 pm
rapp
Why Rapport Therapeutics (RAPP) Is Up 6.3% After Positive Phase 2a Epilepsy Drug Results and Analyst Optimism [Yahoo! Finance]
Low
Report
Why Rapport Therapeutics (RAPP) Is Up 6.3% After Positive Phase 2a Epilepsy Drug Results and Analyst Optimism [Yahoo! Finance]
9/30
12:13 pm
rapp
JMP Sees Big Gains in Rapport Therapeutics, Inc. (RAPP) After Focal Epilepsy Study Success [Yahoo! Finance]
Neutral
Report
JMP Sees Big Gains in Rapport Therapeutics, Inc. (RAPP) After Focal Epilepsy Study Success [Yahoo! Finance]